CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · IEX Real-Time Price · USD
6.35
-0.09 (-1.40%)
At close: Jul 19, 2024, 4:00 PM
6.27
-0.08 (-1.26%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
CASI Pharmaceuticals Revenue
In the year 2023, CASI Pharmaceuticals had annual revenue of $33.88M. Revenue in the quarter ending December 31, 2023 was $6.87M.
Revenue (ttm)
$33.88M
Revenue Growth
-21.41%
P/S Ratio
2.51
Revenue / Employee
$192,494
Employees
176
Market Cap
85.10M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 33.88M | -9.23M | -21.41% |
Dec 31, 2022 | 43.11M | 12.94M | 42.89% |
Dec 31, 2021 | 30.17M | 15.03M | 99.25% |
Dec 31, 2020 | 15.14M | 11.01M | 266.52% |
Dec 31, 2019 | 4.13M | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 47.71K | 23.99K | 101.09% |
Dec 31, 2014 | 23.73K | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 669.31K | -1.27M | -65.52% |
Dec 31, 2011 | 1.94M | -1.75M | -47.45% |
Dec 31, 2010 | 3.69M | -1.59M | -30.11% |
Dec 31, 2009 | 5.28M | -2.19M | -29.33% |
Dec 31, 2008 | 7.48M | 81.57K | 1.10% |
Dec 31, 2007 | 7.40M | 501.29K | 7.27% |
Dec 31, 2006 | 6.89M | 976.30K | 16.50% |
Dec 31, 2005 | 5.92M | 5.40M | 1,051.38% |
Dec 31, 2004 | 514.00K | -1.06M | -67.38% |
Dec 31, 2003 | 1.58M | 399.06K | 33.92% |
Dec 31, 2002 | 1.18M | -685.45K | -36.81% |
Dec 31, 2001 | 1.86M | -1.81M | -49.29% |
Dec 31, 2000 | 3.67M | -1.35M | -26.82% |
Dec 31, 1999 | 5.02M | -143.93K | -2.79% |
Dec 31, 1998 | 5.16M | 404.00K | 8.49% |
Dec 31, 1997 | 4.76M | 132.49K | 2.86% |
Dec 31, 1996 | 4.63M | 3.91M | 550.34% |
Dec 31, 1995 | 711.17K | 620.98K | 688.57% |
Dec 31, 1994 | 90.19K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alpha Teknova | 36.85M |
DBV Technologies | 14.94M |
Hyperfine | 11.69M |
Clearside Biomedical | 8.45M |
Benitec Biopharma | 7.00K |
CASI News
- 2 days ago - CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - PRNewsWire
- 13 days ago - CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP - PRNewsWire
- 25 days ago - CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company - PRNewsWire
- 25 days ago - CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He - PRNewsWire
- 2 months ago - CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) - PRNewsWire
- 2 months ago - CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - PRNewsWire
- 4 months ago - CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS - PRNewsWire
- 4 months ago - CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China - PRNewsWire